Saturday, July 11, 2026

Drug profile · INN

clavulanate potassium

clavulanate potassium (TIMENTIN) is a bacterial beta-lactamase tem inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — clavulanate potassium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

clavulanate potassium (TIMENTIN) is a bacterial beta-lactamase tem inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN clavulanate potassium
Brand TIMENTIN
Mechanism Bacterial beta-lactamase TEM inhibitor
Target Beta-lactamase TEM
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Bacterial beta-lactamase TEM inhibitor

Primary target: Beta-lactamase TEM

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. avibactam sodium Bacterial beta-lactamase TEM inhibitor

Frequently asked questions

What is clavulanate potassium?

clavulanate potassium (TIMENTIN) is a bacterial beta-lactamase tem inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for clavulanate potassium?

TIMENTIN is a marketed brand name for clavulanate potassium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of clavulanate potassium?

clavulanate potassium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.